Kornimate/medical-research-clean huggingface dataset:
mandala intervention on mental distress in nurses working with terminally ill patients

Conditions: Mental Health Issue

Summary: mandala application intervention of mental distress in nurses working with terminally ill patients

questionnaires were applied to the control and experimental groups. mandala painting was done to the experimental group. questionnaires were applied to the control and experimental groups again. distress, anxiety, depression, death anxiety, death depression and psychological well-being of the experimental and control groups were evaluated.

Eligibility criteria:
inclusion criteria: volunteer * active employee * year of study exclusion criteria: * paint allergy * use of psychiatric drugs loss of loved one in the last six months

Keywords: mental health, anxiety, depression
relative bioavailability study of nirmatrelvir/ritonavir 4 different fixed dose combination tablets relative to the commercial tablets in healthy participants

Conditions: Biological Availability; Healthy Participants

Summary: the purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different fdc tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult participants.


Eligibility criteria:
inclusion criteria: * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination (pe), laboratory tests, vital signs and standard 12 lead ecgs. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures exclusion criteria: * positive test result for sars-cov-2 infection at the time of screening or day -1. * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy or brady arrhythmias) or indicating serious underlying heart disease (eg, prolonged pr interval, cardiomyopathy, heart failure greater than new york heart association (nyha) 1, underlying structural heart disease, wolff parkinson-white syndrome). * any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c; positive testing for hiv, hepatitis b surface antigen (hbsag), or hepatitis b surface antibody (hcvab). hepatitis b vaccination is allowed. * use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. * participant who have received a covid-19 vaccine within 7 days before screening or admission, or who are to be vaccinated with a covid-19 vaccine at any time during the study confinement period. * a positive urine drug test.

Keywords: coronavirus disease 2019 (covid-19) severe acute respiratory syndrome coronavirus 2 (sars-cov-2) nirmatrelvir paxlovid
a study of delavirdine mesylate in combination with other anti-hiv drugs in hiv-infected children and babies

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give delavirdine mesylate (rescriptor) plus two nucleoside reverse transcriptase inhibitors (nrtis) to hiv-infected children and babies. this study also examines how the body processes rescriptor when taken with 2 nrtis.


Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * plasma hiv-1 levels greater than 10,000 copies/ml.

Keywords: hiv-1 drug therapy, combination delavirdine reverse transcriptase inhibitors
effectiveness-implementation evaluation of acute kidney injury decision support

Conditions: Acute Kidney Injury

Summary: study purpose: this study is testing an artificial intelligence (ai)-powered clinical decision support (cds) system designed to help emergency department (ed) doctors detect and manage acute kidney injury (aki) earlier. the goal is to see whether the tool improves patient care, clinician decision-making, and hospital outcomes when used in real-world ed settings. study design: the ai tool will be gradually introduced at three hospital eds: johns hopkins hospital (jhh) bayview medical center (bmc) howard county general hospital (hcgh) before the tool is activated, it will run in the background to collect baseline data without influencing care. once implemented, doctors will receive training, and researchers will track how often the tool is used and whether it improves aki care. what the study measures: process outcomes: does the tool help doctors identify aki sooner, avoid harmful medications, and improve decision-making about hospitalization? clinical outcomes: does the tool reduce the number and severity of aki cases and improve kidney-related health outcomes? implementation outcomes: do ed doctors find the tool useful? does it fit into the ed doctor's workflow without slowing the ed doctor's down? expected impact: if successful, the ai tool could be expanded to other hospitals and used to improve early detection and treatment of aki, reducing kidney complications and improving patient care nationwide.


Eligibility criteria:
inclusion criteria: participants must meet all of the following conditions to be eligible for the study: 1. emergency department visit patients presenting to one of the three study site emergency departments (eds): johns hopkins hospital (jhh) bayview medical center (bmc) howard county general hospital (hcgh) serum creatinine measurement 2. at least one serum creatinine (scr) test performed during the ed visit. 3. age: adults (≥18 years old) at the time of ed visit. 4. follow-up data available: to be included in analysis for the investigator's secondary effectiveness outcome (new or progressive aki) patients must have repeat creatinine concentration measurement available within 72 hours exclusion criteria: 1. no ed serum creatinine data: patients who do not have a measured serum creatinine (scr) value during the ed visit will not have decision support provided during the ed stay. 2. patients discharged without follow-up data: patients discharged from the ed who do not undergo a follow-up serum creatinine test within 72 hours will be excluded from analysis of new or progressive aki outcome assessment. 3. age \<18 years 4. end-stage kidney disease (eskd) or chronic dialysis: patients with a documented history of end-stage kidney disease (eskd), (patients receiving chronic dialysis (hemodialysis or peritoneal dialysis) will will be excluded from analysis of new or progressive aki outcome assessment).

Keywords: acute kidney injury aki prediction machine learning emergency department clinical decision support
open-label rollover study of levosimendan in ph-hfpef patients

Conditions: Hypertension Pulmonary Secondary Heart Failure; Right Sided Heart Failure With Normal Ejection Fraction; Heart Failure With Normal Ejection Fraction

Summary: ph-hfpef patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.

this study will enroll ph-hfpef patients that have completed a controlled levosimendan study. these patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.

Eligibility criteria:
inclusion criteria: 1. provide a personally signed and dated informed consent document prior to initiation of any study-related procedures that are not considered standard of care. 2. completed double-blind therapy in a ph-hfpef clinical study sponsored by tenax therapeutics, inc. 3. may, in the opinion of the investigator, benefit from continued levosimendan treatment. 4. female patients of childbearing potential must agree to use a highly effective method of contraception. 5. willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. exclusion criteria: 1. discontinued treatment in the parent study for any reason other than study completion or sponsor termination of the study. 2. pregnant or breastfeeding women. 3. local access to commercially available levosimendan 4. inability to comply with planned study procedures 5. patients with scheduled lung or heart transplant or cardiac surgery 6. dialysis developed since enrollment in parent study (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration) 7. estimated glomerular filtration rate (egfr) \<30 ml/min/1.73m2 8. liver dysfunction with child pugh class b or c (see attachment 2) 9. evidence of systemic bacterial, systemic fungal, or viral infection refractory to treatment 10. weight \>150kg 11. systolic blood pressure (sbp) cannot be managed to ensure sbp \>100 mmhg at initiation of study drug 12. heart rate \>100 bpm with study drug, persistent for at least 10 minutes at screening. 13. hemoglobin \< 80 g/l 14. serum potassium \ 5.5 mmol/l at baseline that is unresponsive to management
cross-sectional and prospective study to characterize early-onset presbycusis

Conditions: Sensorineural Hearing Loss, Bilateral

Summary: the purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on gjb2 gene.

this study aims to characterize patients with adulthood-onset bilateral sensorineural hearing loss not due to any underlying medical condition (likely due to a genetic cause) and to assess the evolution of hearing impairment of those carrying mutations in gjb2 gene. patients who present with adulthood-onset bilateral sensorineural hearing loss will be screened for the presence of mutation involved in hearing impairment. patients with gjb2 mutations will be proposed to continue in a follow-up period.

Eligibility criteria:
inclusion criteria: 1. female or male patients ≥30 and ≤55 years old 2. bilateral hearing loss first noticed after the age of 16 years old 3. documented genotyping results showing mutations in gjb2 gene. exclusion criteria: 1. deafness with a known, non-genetic cause 2. to the opinion of the investigator, unable and/or unwilling to comply with all the protocol requirements and/or study procedures

Keywords: adulthood-onset bilateral sensorineural hearing loss gjb2 presbycusis hearing impairement deafness connexin 26 song genetic deafness adult deafness
safety and efficacy maintenance study of quetiapine sr to treat gad patients.

Conditions: Anxiety Disorders

Summary: the primary objective of this study is to evaluate the efficacy of quetiapine sr compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (gad). please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * patients will be male or female, 18 to 65 years of age (inclusive), with a diagnosis of gad according to dsm-iv criteria 300.02 as assessed by the mini. exclusion criteria: * patients suffering from depressive symptoms, defined as having a montgomery-åsberg depression rating scale (madrs) total score of 17 or more at the enrolment visit, will be excluded from participation in this study.

Keywords: generalised anxiety disorder
safety and efficacy of mirazid for schistosomiasis treatment

Conditions: Schistosoma Hematobium Infection; Schistosomiasis Mansoni

Summary: clinical trial phase:phase iii primary objectives: * compare mirazid and praziquantel cure rates for both schistosoma species. * compare mirazid and praziquantel effect in lowering the intensity of infection for both schistosoma species. secondary objective:identify and compare the types and severity of side and adverse effects between the mirazid and praziquantel. study population:200 schistosomiasis infected persons of both types of schistosomiasis aged from 15-35 years. those subjects will be selected from among those screened.subjects will include both genders excluding chronically ill such as chronic liver disease patients and those with both types of schistosomiasis. recruitment period:3 months and subjects follow up for another 3 months followed by 3 months for statistical analysis and report writing study duration: total study duration is expected to be 9 months: 3 months for recruitment, 3 months for follow up and 3 months for data management and report writing. endpoints: will be measured at 3 months of successful administration of treatment either mirazid or praziquantel as per the randomization scheme. by then, final assessment of the response to treatment will be done by examining urine or stool of the subject for presence of schistosoma eggs and its density if found. three negative urine or stool samples collected 2-days apart at 12 weeks post treatment will indicate treatment success. one positive sample collected at week 12 will indicate infection with schistosomiasis.

study design:this is a phase iii, open-label randomized non-placebo-controlled study in which the investigators will compare the efficacy and safety of mirazid to praziquantel as a treatment for schistosomiasis. after screening, positive subjects for one of the schistosomiasis will be recruited in the study. they will be treated by mirazid as 600 mg oral (soft gelatin capsules) for 6 consecutive days or 40mg/kg body weight of praziquantel as a single oral dose. subjects will be evaluated for success of treatment at 12 weeks of treatment. evaluation will be done by examining urine or stool samples for schistosomiasis including egg counts for the positive cases.

Eligibility criteria:
inclusion criteria: * adolescent and young adults aged 15-30 years * positive for schistosoma infection of any type. exclusion criteria: * mixed schistosoma infection of both types * history of administration of treatment for schistosoma infection in the last 6 months prior to the study. * severely ill patients * advanced chronic liver disease.

Keywords: schistosomiasis hematobium schistosomiasis mansoni
comparisons of clinical outcomes between novel tailored transvaginal mesh surgery and vaginal native tissue repair surgery for pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: the issue of whether utilizing the mesh in the surgical treatment of pelvic organ prolapse remained undetermined.thus, the aim of this study is to analyze clinical outcome of women who underwent pelvic organ prolapse surgeries with and without mesh implantation in the department of obstetrics \& gynecology of national taiwan university hospital.

hypothesis / aims of study: the use of mesh for women with pelvic organ prolapsed (pop) remains under debate, despite a recent randomized trial reported a favourable anatomic outcome of transvaginal mesh (tvm) surgery for cystocele, compared with anterior colporrhaphy. besides, the issue of preserving uterus or not in women with pop during operation is still undetermined. thus, the aim of this study is to compare clinical outcomes of the novel tailored tvm surgeries and conventional transvaginal native tissue repair (ntr) surgeries for pop. study design, materials and methods: between november 2011 and september 2014, the medical records of all consecutive women who underwent pop surgeries in a medical centre were reviewed. the choice of surgery method was according to the surgeons' preference. clinical characteristics and intraoperative data and postoperative clinical outcomes were recorded. wilcoxon rank-sum test was used to compare the data between two groups. kaplan-meier survival analysis was used to compare the recurrence rate between two groups.

Eligibility criteria:
inclusion criteria: * all women who underwent surgical treatment of pelvic organ prolapse were enrolled in this study. * ≥ 20 years old female. exclusion criteria: * healthy women * without underwent surgical treatment of pelvic organ prolapse

Keywords: pelvic organ prolapse pelvic floor reconstruction surgery transvaginal mesh surgery women surgical treatment
to study the effect of organic light emitting diodes (oled) on cultured fibroblast

Conditions: Non-pressure Chronic Ulcer of Skin, Not Elsewhere Classified

Summary: chronic ulcers is a common clinical problem. diabetes or peripheral vascular occlusion is major reason leading to chronic wound healing. the investigators's previous animal experiments have confirmed that oled can promote burn wound healing and fibroblast proliferation in normal wistar rat. in order to find the time point and dosage of the effective light therapy. the investigators further use cultured human fibroblasts in vitro to study light therapy to promote fibroblast proliferation mechanisms. expect clinical application of light therapy in the future is more accurate and effective.

chronic ulcers is a common clinical problem. diabetes or peripheral vascular occlusion is major reason leading to chronic wound healing. therapeutic methods to promote wound healing are hyperbaric oxygen therapy, vacuum assisted therapy and photostimulation. although there are many treatments but no one has been widely accepted. the clinical effects of uncertainty, high cost and inconvenience of use is the main reason. each year amputation of the population due to chronic ulcers has not decreased. in order to break the current medical difficulties, we refer to the new light therapy technology. look forward to shorten the healing time and reduce medicine costs. the investigators's previous animal experiments have confirmed that oled can promote burn wound healing and fibroblast proliferation in normal wistar rat. in order to find the time point and dosage of the effective light therapy. the investigators further use cultured human fibroblasts in vitro to study light therapy to promote fibroblast proliferation mechanisms. expect clinical application of light therapy in the future is more accurate and effective irradiative time points and dosage.

Eligibility criteria:
inclusion criteria: * chronic ulcer * normal skin * age 50\~80 years, * chronic skin ulcer patient * skin-grafting patient exclusion criteria:
a study of olaratumab (imc-3g3) in prostate cancer

Conditions: Prostate Cancer

Summary: this is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically-confirmed adenocarcinoma of the prostate * radiographic evidence of metastatic prostate cancer (stage m1 or d2) * has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of \<50 nanograms per milliliter (ng/ml) * has had disease progression or intolerance on docetaxel-based therapy * prostate-specific antigen (psa) ≥10 ng/ml * all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to ≤grade 1, based on national cancer institute common terminology criteria for adverse events (nci ctcae) version (v) 4.02 * participant has an eastern cooperative oncology group (ecog) performance status 0-2 * adequate hematologic function * adequate hepatic function * adequate renal function * urinary protein is ≤1 on dipstick or routine analysis * life expectancy of more than 3 months * fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study * signed informed consent document exclusion criteria: * concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms * the participant has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease * prior therapy with mitoxantrone for advanced prostate cancer * the participant has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is ≥10% below the lower limit of normal institutional range * history of prior treatment with other agents that directly inhibit platelet-derived growth factor (pdgf) or platelet-derived growth factor receptors (pdgfr) * known allergy to any of the treatment components: olaratumab, mitoxantrone, and/or prednisone * radiotherapy within 21 days prior to first dose of olaratumab * any investigational therapy within 30 days of randomization * is receiving corticosteroids at a dose \>5 mg prednisone po bid or equivalent * received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain * has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders * known or suspected brain or leptomeningeal metastases * known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness

Keywords: prostate cancer
platelet-rich plasma for stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: stress urinary incontinence (sui) is defined by the international continence society (ics) as "the complaint of any involuntary loss of urine on effort or physical exertion or on sneezing or coughing. the treatment varies from kegel exercise, bulking agents, vaginal laser, to surgery. platelet-rich plasma (prp) stimulates angiogenesis, promoting vascular in-growth and fibroblast proliferation, enhancing wound-healing in both soft and hard tissue. prp regulates tissue reconstruction and has been previously used in orthopedics and plastic surgery. the previous study revealed some promising results for prp use in pelvic floor dysfunction, including sui. we aim to evaluate the effect of prp on female sui.

women with sui were enrolled. pre-treatment evaluation included overactive bladder symptom score (oabss), international consultation on incontinence questionnaire-urinary incontinence short form (iciq-ui), pelvic organ prolapse distress inventory 6 (popdi-6), female sexual function index (fsfi), urinary distress inventory short form (udi-6), incontinence impact questionnaire, short form (iiq-7), pelvic examination, and urodynamic study (uds) (including pad test). 10 milliliter blood was taken from each participant. the regenkit-tht (regenlab sa, switzerland) was used to separation of plasma and blood cells. 3 milliliter prp was extracted from the bottom of the plasma. prp was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia. the participants received one treatment per month for three times. follow-up schedule is as below: 1st month (transperineal ultrasound and questionnaires), 3rd month (uds and questionnaires), 6th month (questionnaires), and 12th month (questionnaires).

Eligibility criteria:
inclusion criteria: * women with sui * age between 20 to 85 years exclusion criteria: * under anti-platelet agent treatment * under nsaids * platelet dysfunction syndrome * critical thrombocytopenia * hypofibrionogenaemia * sepsis * acute and chronic infections * chronic liver disease * anti-coagulation therapy * history of malignancy * pregnancy

Keywords: stress urinary incontinence platelet-rich plasma